164 related articles for article (PubMed ID: 15721761)
1. The in vivo characteristics of genetically engineered divalent and tetravalent single-chain antibody constructs.
Wittel UA; Jain M; Goel A; Chauhan SC; Colcher D; Batra SK
Nucl Med Biol; 2005 Feb; 32(2):157-64. PubMed ID: 15721761
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and biodistribution of 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49.
Chauhan SC; Jain M; Moore ED; Wittel UA; Li J; Gwilt PR; Colcher D; Batra SK
Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):264-73. PubMed ID: 15791435
[TBL] [Abstract][Full Text] [Related]
3. Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct.
Pavlinkova G; Booth BJ; Batra SK; Colcher D
Clin Cancer Res; 1999 Sep; 5(9):2613-9. PubMed ID: 10499640
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and biodistribution of genetically-engineered antibodies.
Colcher D; Pavlinkova G; Beresford G; Booth BJ; Choudhury A; Batra SK
Q J Nucl Med; 1998 Dec; 42(4):225-41. PubMed ID: 9973838
[TBL] [Abstract][Full Text] [Related]
5. Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: improved biodistribution and potential for therapeutic application.
Goel A; Colcher D; Baranowska-Kortylewicz J; Augustine S; Booth BJ; Pavlinkova G; Batra SK
Cancer Res; 2000 Dec; 60(24):6964-71. PubMed ID: 11156397
[TBL] [Abstract][Full Text] [Related]
6. Single-Dose versus fractionated radioimmunotherapy of human colon carcinoma xenografts using 131I-labeled multivalent CC49 single-chain fvs.
Goel A; Augustine S; Baranowska-Kortylewicz J; Colcher D; Booth BJ; Pavlinkova G; Tempero M; Batra SK
Clin Cancer Res; 2001 Jan; 7(1):175-84. PubMed ID: 11205906
[TBL] [Abstract][Full Text] [Related]
7. Antiepidermal growth factor variant III scFv fragment: effect of radioiodination method on tumor targeting and normal tissue clearance.
Shankar S; Vaidyanathan G; Kuan CT; Bigner DD; Zalutsky MR
Nucl Med Biol; 2006 Jan; 33(1):101-10. PubMed ID: 16459265
[TBL] [Abstract][Full Text] [Related]
8. Divalent forms of CC49 single-chain antibody constructs in Pichia pastoris: expression, purification, and characterization.
Goel A; Beresford GW; Colcher D; Pavlinkova G; Booth BJ; Baranowska-Kortylewicz J; Batra SK
J Biochem; 2000 May; 127(5):829-36. PubMed ID: 10788792
[TBL] [Abstract][Full Text] [Related]
9. A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy.
Schultz J; Lin Y; Sanderson J; Zuo Y; Stone D; Mallett R; Wilbert S; Axworthy D
Cancer Res; 2000 Dec; 60(23):6663-9. PubMed ID: 11118050
[TBL] [Abstract][Full Text] [Related]
10. Binding characteristics and tumor targeting of a covalently linked divalent CC49 single-chain antibody.
Beresford GW; Pavlinkova G; Booth BJ; Batra SK; Colcher D
Int J Cancer; 1999 Jun; 81(6):911-7. PubMed ID: 10362138
[TBL] [Abstract][Full Text] [Related]
11. Biological comparison of 149Pm-, 166Ho-, and 177Lu-DOTA-biotin pretargeted by CC49 scFv-streptavidin fusion protein in xenograft-bearing nude mice.
Lewis MR; Zhang J; Jia F; Owen NK; Cutler CS; Embree MF; Schultz J; Theodore LJ; Ketring AR; Jurisson SS; Axworthy DB
Nucl Med Biol; 2004 Feb; 31(2):213-23. PubMed ID: 15013487
[TBL] [Abstract][Full Text] [Related]
12. Pretargeted radioimmunotherapy of mesothelin-expressing cancer using a tetravalent single-chain Fv-streptavidin fusion protein.
Sato N; Hassan R; Axworthy DB; Wong KJ; Yu S; Theodore LJ; Lin Y; Park L; Brechbiel MW; Pastan I; Paik CH; Carrasquillo JA
J Nucl Med; 2005 Jul; 46(7):1201-9. PubMed ID: 16000290
[TBL] [Abstract][Full Text] [Related]
13. Penetratin improves tumor retention of single-chain antibodies: a novel step toward optimization of radioimmunotherapy of solid tumors.
Jain M; Chauhan SC; Singh AP; Venkatraman G; Colcher D; Batra SK
Cancer Res; 2005 Sep; 65(17):7840-6. PubMed ID: 16140953
[TBL] [Abstract][Full Text] [Related]
14. Engineered single chain antibody fragments for radioimmunotherapy.
Huhalov A; Chester KA
Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):279-88. PubMed ID: 15640791
[TBL] [Abstract][Full Text] [Related]
15. 99mTc-labeled divalent and tetravalent CC49 single-chain Fv's: novel imaging agents for rapid in vivo localization of human colon carcinoma.
Goel A; Baranowska-Kortylewicz J; Hinrichs SH; Wisecarver J; Pavlinkova G; Augustine S; Colcher D; Booth BJ; Batra SK
J Nucl Med; 2001 Oct; 42(10):1519-27. PubMed ID: 11585867
[TBL] [Abstract][Full Text] [Related]
16. In vivo targeting of malignant melanoma by 125Iodine- and 99mTechnetium-labeled single-chain Fv fragments against high molecular weight melanoma-associated antigen.
Kang N; Hamilton S; Odili J; Wilson G; Kupsch J
Clin Cancer Res; 2000 Dec; 6(12):4921-31. PubMed ID: 11156253
[TBL] [Abstract][Full Text] [Related]
17. Effects of genetic engineering on the pharmacokinetics of antibodies.
Colcher D; Goel A; Pavlinkova G; Beresford G; Booth B; Batra SK
Q J Nucl Med; 1999 Jun; 43(2):132-9. PubMed ID: 10429508
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts.
Pavlinkova G; Beresford GW; Booth BJ; Batra SK; Colcher D
J Nucl Med; 1999 Sep; 40(9):1536-46. PubMed ID: 10492377
[TBL] [Abstract][Full Text] [Related]
19. Monospecific bivalent scFv-SH: effects of linker length and location of an engineered cysteine on production, antigen binding activity and free SH accessibility.
Albrecht H; Denardo GL; Denardo SJ
J Immunol Methods; 2006 Mar; 310(1-2):100-16. PubMed ID: 16499921
[TBL] [Abstract][Full Text] [Related]
20. A physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain Fv constructs.
Davda JP; Jain M; Batra SK; Gwilt PR; Robinson DH
Int Immunopharmacol; 2008 Mar; 8(3):401-13. PubMed ID: 18279794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
